- The European Commission approves the use of Pfizer's (NYSE:PFE) XALKORI (crizotinib) as first-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Its previous indication was for the second-line treatment of NSCLC.
- The data supporting the expanded label was generated by the Phase 3 PROFILE 1014 study.
- XALKORI was the first ALK inhibitor cleared in the EU, China, U.S. and Japan. It is commercially available in more than 85 countries. More than 20K patients have been treated to date.